Assessing EGFR ‐mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy

ConclusionsThe presence of BoM is a negative prognostic factor for NSCLC patients with an EGFR mutation, possibly due to the presence of extrathoracic metastases. However, adding AAT and denosumab, along with sequential osimertinib, to the treatment regimen for patients with BoM can improve survival outcomes.

Source: Cancer Medicine - March 29, 2024 Category: Cancer & Oncology Authors: Wei ‐Chun Chen, Wen‐Chien Cheng, Chieh‐Lung Chen, Wei‐Chih Liao, Chia‐Hung Chen, Hung‐Jen Chen, Chih‐Yen Tu, Chi‐Chen Lin, Te‐Chun Hsia Tags: RESEARCH ARTICLE Source Type: research